Journal Policies
Scope of the Journal
Publication ethics
Experimental ethics
Clinical trials
Peer review process
Press embargos
Self-archiving policy
Drug disclaimer
Material disclaimer
Scope of the journal
The Journal of Hip Preservation Surgery is a Gold Open Access journal dedicated to publishing research related to hip preservation surgery and is aimed at authors and readers who are active in this field. Subject areas will broadly cover: 1) hip arthroscopic surgery, 2) open hip preservation surgery, 3) laboratory and clinical research related to hip preservation surgery. The Journal of Hip Preservation Surgery encourages submissions that are research-question driven and welcomes clinical studies with outcome measures and follow-up periods of adequate length. Although the Journal focuses on pre-arthroplasty approaches to hip preservation, submissions that concern arthroplasty directly related to joint preservation may still be considered at the discretion of the Editors. Case reports will generally not be published, unless exceptional, and may be returned without review.
Publication ethics
Authors should observe high standards with respect to publication ethics as set out by the Commission on Publication Ethics (COPE) and International Committee of Medical Journal Editors (ICMJE). Falsification or fabrication of data, plagiarism, including duplicate publication of the author's own work without proper citation, and misappropriation of the work are all unacceptable practices. Any cases of ethical misconduct are treated very seriously and will be dealt with in accordance with the COPE guidelines.
Authorship
All authors listed on the manuscript should have contributed significantly to the experimental design, its implementation, or analysis and interpretation of the data. All authors should have been involved in the writing of the manuscript at draft and any revision stages, and have read and approved the final version. Anyone who made major contributions to the writing of the manuscript should be listed as an author (e.g. 'ghost writing' is prohibited by the Journal) provided that the number of authors remains within the limit set by the journal (please see manuscript preparation instructions for details). Any other individuals who made less substantive contributions to the experiment or the writing of the manuscript should be listed in the Acknowledgement section. Any change in authorship (including author order) after the initial manuscript submission must be approved in writing by all authors.
Authorship and 'Umbrella' groups
Many large collaborative studies are organized under a group name which represents all the participants. All articles must have at least one named individual as author. Authors who wish to acknowledge the umbrella group from which the data originate should first list the author(s) of the article and follow this with 'on behalf of the GROUP NAME'. If necessary the names of the participants may be listed in the Acknowledgements section.
Plagiarism
Manuscripts submitted may be screened with iThenticate anti-plagiarism software in an attempt to detect and prevent plagiarism. Any manuscript may be screened, especially if there is reason to suppose part or all of the text has been previously published. Prior to final acceptance any manuscript that has not already been screened may be put through iThenticate. Please see more information about iThenticate.
Conflicts of interest
At the point of submission, each author should reveal any financial interests or connections, direct or indirect, or other situations that might raise the question of bias in the work reported or the conclusions, implications, or opinions stated – including pertinent commercial or other sources of funding for the individual author(s) or for the associated department(s) or organization(s), personal relationships, or direct academic competition. When considering whether you should declare a conflicting interest or connection please consider the conflict of interest test: Is there any arrangement that would embarrass you or any of your co-authors if it was to emerge after publication and you had not declared it?
As part of the online submission process, corresponding authors are required to confirm whether they or their co-authors have any conflicts of interest to declare, and in the case of an existing conflict of interest that this is fully declared.
Authors should also include a Conflict of Interest statement in their submitted manuscript.
If the manuscript is published, Conflict of Interest information, including if none was declared, will be communicated in a statement in the published paper.
Experimental ethics
Animal experiments
When reporting animal experiments authors should indicate whether the institution’s, national research council’s, or any other law on the care and use of laboratory animals was followed.
Human subjects
When reporting on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the Helsinki Declaration (1964, amended most recently in 2008) of the World Medical Association. Manuscripts should include a statement that the patient’s written consent was obtained and any information, including illustrations, should be as anonymized as far as possible. Authors should indicate that the design of the work has been approved by local ethical committees or that it conforms to standards currently applied in the country of origin. The name of the authorizing body should be stated in the paper.
Clinical trials
Registering clinical trials
In accordance with the Clinical Trial Registration Statement from the International Committee of Medical Journal Editors (ICMJE) all clinical trials published in the journal must be registered in a public trials registry at or before the onset of participant enrolment. For any clinical trials commencing prior to 2008, retrospective registration will be accepted.
The registry must be accessible to the public at no charge, searchable, open to all prospective registrants, managed by a not-for-profit organization, and include all the necessary information as specified by the ICMJE. A list of recommended registries can be found on the ICMJE website. Results posted in the same clinical trials registry in which the primary registration resides will not be considered prior publication if they are presented in the form of a brief abstract (<500 words or less) or a table.
Authors are requested to provide the exact URL and unique identification number for the trial registration at the time of submission. This information will be published in the article and we ask that you include the URL and identification number on the title page of your manuscript.
Reporting clinical trials
Clinical trials should comply with the Consolidated Standards of Reporting Trials Statement (CONSORT), which is available here. Authors reporting on randomized clinical trials (RCT) should consult the CONSORT checklist when preparing their manuscripts. All RCT data will be evaluated in accordance with the rules and checklist of the CONSORT statement.
Other types of studies should follow guidelines where available. These include STARD (Standards for the Reporting of Diagnostic accuracy studies), STROBE (Strengthening the reporting of observational studies in epidemiology), PRISMA (Transparent Reporting of Systematic Reviews and Meta-Analyses) and MOOSE (Meta-analyses of observational studies). For further information on good reporting of health research studies please go to the EQUATOR network.
Peer review process
This journal operates double-anonymised peer review, meaning that the authors’ identities are hidden from the reviewers, and the reviewers’ identities are hidden from the authors. The identities of the authors and the reviewers are known to the Editor. For full details about the peer review process, see Fair editing and peer review
OUP author FAQs.
All submissions to the journal are initially reviewed by the Editor and his Associates. At this stage manuscripts may be rejected without peer review if it is felt that they are not of high enough priority or not relevant to the journal. This fast rejection process means that authors are given a quick decision and do not need to wait for the review process. Manuscripts that are not instantly rejected are sent out for peer review, usually to two independent reviewers. Based on the feedback from these reviewers and the Editors’ judgment a decision is given on the manuscript.
Manuscripts may also be sent out for statistical review.
The average time from submission to first decision is 30 days.
Press embargos
Occasionally the journal will issue press releases for some of its articles. Authors submitting to the journal are expected to respect any press embargos set for their manuscript.
Self-archiving policy
For information about this journal's policy, please visit our Author Self-Archiving policy page.
Drug disclaimer
The mention of trade names, commercial products or organizations, and the inclusion of advertisements in the Journal of Hip Preservation Surgery does not imply endorsement by the Society, the Editors, the Editorial board, Oxford University Press or the organization to which the authors are affiliated. The Editors and publishers have taken all reasonable precautions to verify drug names and doses, the results of experimental work and clinical findings published in Journal of Hip Preservation Surgery. The ultimate responsibility for the use and dosage of drugs mentioned in Journal of Hip Preservation Surgery and in the interpretation of published material lies with the medical practitioner, and the Editors and publishers cannot accept liability for damages arising from any errors or omissions in Journal of Hip Preservation Surgery. Please inform the Editors of any errors.
Material disclaimer
The opinions expressed in Journal of Hip Preservation Surgery are those of the authors and contributors, and do not necessarily reflect those of the Society the Editors, the Editorial board, Oxford University Press or the organization to which the authors are affiliated.
